Residency · Residency · Cardiothoracic Surgery
Vasoplegia and Vasopressor Management After Cardiac Surgery
Introduction
Vasoplegia (vasoplegic syndrome) is a state of pathological vasodilation characterized by refractory hypotension, low systemic vascular resistance (SVR), and normal or elevated cardiac output following cardiac surgery. It occurs in 5-25% of patients undergoing cardiopulmonary bypass (CPB) and is associated with significantly increased morbidity and mortality.
Pathophysiology
Mechanisms of Vasodilation
The systemic inflammatory response syndrome (SIRS) triggered by CPB, blood-circuit contact, and ischemia-reperfusion injury drives vasoplegia. Excessive production of nitric oxide (NO) occurs through activation of inducible nitric oxide synthase (iNOS). Inflammatory mediators including interleukins (IL-6, IL-8, IL-10), complement activation products (C3a, C5a), and tumor necrosis factor-alpha (TNF-alpha) amplify the response. Vasopressin deficiency develops from depletion of hypothalamic-pituitary stores during prolonged CPB. Activation of ATP-sensitive potassium channels (K-ATP channels) leads to vascular smooth muscle relaxation.
Risk Factors
Risk factors for vasoplegia include prolonged CPB time (exceeding 120 minutes), preoperative use of ACE inhibitors, ARBs, or calcium channel blockers, left ventricular ejection fraction below 35%, preoperative use of intravenous heparin or milrinone, heart failure and cardiogenic shock, and redo cardiac surgery or combined procedures.
Diagnostic Criteria
Vasoplegia is diagnosed when mean arterial pressure falls below 60 mmHg despite adequate volume resuscitation, systemic vascular resistance index drops below 1600 dynes/sec/cm-5/m2, cardiac index exceeds 2.2 L/min/m2 (normal or elevated), vasopressors are required within 6 hours of CPB separation, and other causes such as sepsis, anaphylaxis, and adrenal insufficiency have been excluded.
Vasopressor Management
First-Line Agents
Norepinephrine at 0.05-0.5 mcg/kg/min is the preferred first-line agent, providing alpha-1 agonism with mild beta-1 activity. Vasopressin at 0.01-0.04 units/min acts on V1 receptors independent of catecholamine pathways and is particularly effective in vasopressin-depleted states.
| Agent | Dose | Receptor/Mechanism | Line of Therapy | Key Considerations |
|---|---|---|---|---|
| Norepinephrine | 0.05-0.5 mcg/kg/min | Alpha-1 >> Beta-1 | First-line | Preferred initial agent |
| Vasopressin | 0.01-0.04 U/min | V1 receptor (NO-independent) | First/second-line | Synergistic with NE; addresses AVP deficiency |
| Phenylephrine | 0.5-5 mcg/kg/min | Pure alpha-1 | Second-line | Useful when tachycardia limits NE |
| Epinephrine | 0.01-0.1 mcg/kg/min | Alpha + beta | Second-line | For concurrent myocardial dysfunction |
| Angiotensin II (Giapreza) | 20-40 ng/kg/min | AT1 receptor | Refractory | FDA-approved for distributive shock |
| Methylene blue | 1.5-2 mg/kg IV over 20-30 min | Inhibits guanylyl cyclase + iNOS | Rescue | Contraindicated in G6PD deficiency; interferes with SpO2 |
| Hydroxocobalamin | 5 g IV | NO scavenger | Rescue | Alternative to methylene blue |
| Hydrocortisone | 50 mg IV q8h | Anti-inflammatory; adrenal support | Adjunctive | For relative adrenal insufficiency |
Second-Line and Adjunctive Agents
Phenylephrine at 0.5-5 mcg/kg/min is a pure alpha-1 agonist useful when tachycardia limits norepinephrine use. Epinephrine at 0.01-0.1 mcg/kg/min combines alpha and beta agonism and is reserved for concurrent myocardial dysfunction. Angiotensin II (Giapreza) is a synthetic angiotensin II approved for refractory vasoplegia, acting on AT1 receptors. Methylene blue at 1-2 mg/kg IV bolus inhibits guanylyl cyclase and iNOS and is used as rescue therapy in refractory cases.
Methylene Blue Protocol
Methylene blue is administered at 1.5-2 mg/kg IV over 20-30 minutes, with a possible repeat dose at 1 hour if the response is inadequate. Contraindications include G6PD deficiency, concurrent serotonergic agents (risk of serotonin syndrome), and severe renal insufficiency. It interferes with pulse oximetry readings, producing falsely low SpO2.
Corticosteroid Therapy
Hydrocortisone at 50 mg IV every 8 hours may benefit patients with refractory vasoplegia by addressing potential relative adrenal insufficiency. Preoperative single-dose dexamethasone has shown reduction in vasoplegia incidence in some trials. Duration is typically 48-72 hours with taper guided by clinical response.
Monitoring and Endpoints
Monitoring includes continuous arterial blood pressure via arterial line, pulmonary artery catheter or minimally invasive cardiac output monitoring (FloTrac, PiCCO), target MAP above 65 mmHg, SVRI above 1800, mixed venous oxygen saturation (SvO2) above 65%, serial lactate levels to assess end-organ perfusion, and urine output above 0.5 mL/kg/hr as a marker of renal perfusion.
Outcomes and Prognosis
Vasoplegia increases ICU length of stay by 2-4 days on average and is associated with increased rates of acute kidney injury, prolonged ventilation, and multiorgan dysfunction. Mortality rates range from 10-25% in severe refractory vasoplegia. Early recognition and a multimodal vasopressor strategy improve outcomes.
Key Clinical Pearls
Vasoplegia should be suspected when hypotension persists despite adequate cardiac output and volume status; cardiogenic shock, tamponade, and hemorrhage must always be excluded first. Holding ACE inhibitors and ARBs 24-48 hours preoperatively may reduce vasoplegia incidence. Vasopressin addresses the vasopressin-deficient component and acts synergistically with norepinephrine. Methylene blue should be considered early in refractory cases rather than as a last resort. Multimodal vasopressor therapy targeting different receptor pathways is more effective than escalating a single agent.
References
- Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. American Journal of the Medical Sciences. 2015;349(1):80-88.
- Shaefi S, Mittel A, Engelman DT, et al. Vasoplegia after cardiovascular procedures: pathophysiology and targeted therapy. Journal of Cardiothoracic and Vascular Anesthesia. 2018;32(2):1013-1022.
- Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery. Anesthesiology. 2017;126(1):85-93.
- Maslow AD, Stearns G, Butala P, et al. The hemodynamic effects of methylene blue when administered at the onset of cardiopulmonary bypass. Anesthesia & Analgesia. 2006;103(1):2-8.